Abstracts tagged "Late-Breaking 2024"

Abstract Number: L20 • ACR Convergence 2024
Automated Ultrasound System ARTHUR with AI Analysis DIANA Matches Expert Rheumatologist in Hand Joint Assessment of Rheumatoid Arthritis Patients
Bill Aplin Frederiksen¹, Mads Ammitzbøll Danielsen², Hilde Berner Hammer³, Benjamin Schultz Overgaard¹, Anders Weber⁴, Lene Terslev², Thiusius Rajeeth Savarimuthu⁵ and Soren Andreas Just¹, ¹Section of Rheumatology, Department of Medicine, Svendborg Sygehus OUH, Svendborg, Denmark, ²Center for Rheumatology and Spine Disease, Rigshospitalet, Glostrup, Denmark, ³Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, Faculty of Medicine, University of Oslo, Oslo, Norway, ⁴ROPCA, Odense, Denmark, ⁵Mærsk Mc-Kinney Møller Institute, University of Southern Denmark, Odense, Denmark
Background/Purpose: To evaluate the precision of ARTHUR (Figure 1), a CE-marked, fully automated ultrasound scanning system that captures ultrasound images of 22 hand joints and…
Abstract Number: L05 • ACR Convergence 2024
Prolonged Plasma Urate-Lowering After a Single Intravenous Administration of PRX-115, a Novel PEGylated Uricase, in Participants with Elevated Urate Levels
Christian Schwabe¹, Orit Cohen Barak², Alexandra Cole³, Hadar Reuveni², Liron Shelev², Liora Blinder-Haddad² and Nicola Dalbeth⁴, ¹NZCR, Auckland, New Zealand, ²Protalix Ltd, Karmiel, Israel, ³NZCR, Christchurch, New Zealand, ⁴University of Auckland, Auckland, New Zealand
Background/Purpose: PEGylated uricases have already demonstrated therapeutic modality in the treatment of refractory gout patients. PRX-115 is a recombinant homotetrameric uricase enzyme, produced from Candida…
Abstract Number: L06 • ACR Convergence 2024
Distinct Cytokine and Cytokine Receptor Expression Patterns Characterize Different Subtypes of Inflammatory Myopathies
Raphael Kirou¹, Iago Pinal-Fernandez¹ and Andrew Mammen², ¹NIAMS/National Institutes of Health, Bethesda, MD, ²NIH, Bethesda, MD
Background/Purpose: Myositis is a term for a heterogeneous group of inflammatory myopathies, each with characteristic clinical manifestations, histopathological features, and autoantibodies, including myositis-specific autoantibodies (MSAs).…
Abstract Number: L07 • ACR Convergence 2024
The Classification Criteria for Anti-Synthetase Syndrome (Class) Project
Giovanni Zanframundo¹, Sara Faghihi Kashani², Akira Yoshida³, Eduardo Dourado⁴, Iazsmin Bauer Ventura⁵, Daphne Rivero Gallegos⁶, Aravinthan Loganathan⁷, Gianluca Sambataro⁸, Francisca Bozan⁹, Sangmee Bae¹⁰, Darosa Lim¹¹, Marta Cheli¹², Yasuhiko Yamano¹³, Francesco Bonella¹⁴, Tamera Corte¹⁵, Tracy J. Doyle¹⁶, David Fiorentino¹⁷, Miguel Gonzalez-Gay¹⁸, Marie Hudson¹⁹, Masataka Kuwana²⁰, Ingrid Lundberg²¹, Andrew Mammen²², Neil McHugh²³, Frederick Miller²⁴, Carlomaurizio Montecucco¹, Chester Oddis²⁵, Jorge Rojas-Serrano⁶, Jens Schmidt²⁶, Carlo Alberto Scirè²⁷, Albert Selva-O'Callaghan²⁸, Victoria Werth¹¹, Davide Rozza²⁹, Monica Morosini³⁰, Sara Bozzini³⁰, Lorenzo Cavagna¹, Rohit Aggarwal²⁵ and the CLASS project investigators, ¹Università di Pavia, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy, ²University of Pittsburgh School of Medicine, Pittsburgh, PA, USA and University of California, San Francisco, CA, ³Nippon Medical School Graduate School of Medicine, Bunkyo-ku, Tokyo, Japan, ⁴Unidade Local de Saùde da Regiao de Aveiro and Aveiro Rheumatology Research Centre, Aveiro, Portugal; Universidade de Lisboa, Lisboa, Portugal, ⁵University of Chicago, Chicago, IL, ⁶Instituto Nacional de Enfermedades Respiratorias, Ismael Cosío Villegas, Mexico City, Mexico, ⁷Royal National Hospital for Rheumatic Diseases and University of Bath, UK; Arthritis Australia, Broadway, Glebe, NSW, Australia, ⁸University of Enna "Kore", Enna, Italy, ⁹Hospital Clinico Universidad de Chile, Santiago de Chile, Chile, ¹⁰UCLA, Los Angeles, CA, ¹¹University of Pennsylvania, Philadelphia, PA, ¹²Fondazione IRCCS Istituto Neurologico C. Besta, Milano, Italy, ¹³Tosei General Hospital, Aichi, Japan, ¹⁴University of Duisburg-Essen, Essen, Germany, ¹⁵Royal Prince Alfred Hospital and University of Sydney, Sydney, Australia, ¹⁶Brigham and Women's Hospital, Boston, MA, ¹⁷Stanford University, Redwood City, CA, ¹⁸IIS-Fundación Jiménez Díaz, Madrid, Spain, ¹⁹McGill University, Montreal, QC, Canada, ²⁰Nippon Medical School Graduate School of Medicine, Tokyo, Japan, ²¹Karolinska Institutet, Stockholm, Sweden, ²²NIH, Bethesda, MD, ²³University of Bath, Bath, United Kingdom, ²⁴NIH, NIEHS, Durham, NC, ²⁵University of Pittsburgh, Pittsburgh, PA, ²⁶University Medical Center Goettingen, Goettingen, Germany, ²⁷Univeristy of Milano Bicocca, Milan, Italy and IRCCS San Gerardo dei Tintori Foundation, Monza, Italy, ²⁸Hospital Universitari Vall d'Hebron, Barcelona, Spain, ²⁹Italian Society for Rheumatology, Milano, Italy, ³⁰Fondazione IRCCS Policlinico San Matteo Hospital of Pavia, Pavia, Italy
Background/Purpose: The aim of this study was to develop and validate new classification criteria for Anti-Synthetase Syndrome (ASSD) using data and consensus driven methodologies and…
Abstract Number: L08 • ACR Convergence 2024
A Phase 2b, Randomized, Double-blind, Placebo-controlled, Dose-ranging and Parallel-group Study to Evaluate the Safety and Efficacy of XG005 in Subjects with Painful Osteoarthritis of the Knee
Limin Ren¹, Wenjie Zheng², Zhenpeng Guan³, Yang Zhang⁴, Zeyu Huang⁵, Tong Li⁶, Yuwei Peng⁷, Qiuli Wu⁸, Wei Gou⁹, Wei Zhao¹⁰, Pengyan Qiao¹¹, Xiaoli Pan¹² and Guang-Liang Jiang¹³, ¹Peking University, People’s Hospital, Rheumatology and Immunology Department, Beijing, China, ²Yantai Yuhuangding Hospital of Qingdao University, Department of Orthopedics, Yantai, China, ³Peking University, Shougang Hospital, Department of Orthopedics, Beijing, China, ⁴Division of Orthopaedic Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China, ⁵West China Hospital of Sichuan University, Department of Orthopedics, Chengdu, China, ⁶Xiangya Hospital of Central South University, Rheumatology and Immunology Department, Changsha, China, ⁷PingXiang People’s Hospital, Rheumatology and Immunology Department, Pingxiang, China, ⁸Tianjin Medical University General Hospital, Department of Orthopedics, Tianjin, China, ⁹Hebei Petrochina Central Hospital, Rheumatology and Immunology Department, Langfang, China, ¹⁰Central Hospital Affiliated to Shenyang Medical College, Department of Orthopedics, Shenyang, China, ¹¹Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Third Hospital of Shanxi Medical University, Tongji Shanxi Hospital, Rheumatology and Immunology Department, Taiyuan, China, ¹²Affiliated Hospital of Zunyi Medical University, Rheumatology and Immunology Department, Zunyi, China, ¹³Xgene Pharmaceutical, Lexington, MA
Background/Purpose: Osteoarthritis (OA) affects 595 million people globally; cases are projected to increase 49-95% for various joints by 2050 as populations age (GBD 2023). OA…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].